Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 50, Issue 6, 1996, Pages 491-495

  Fjellestad Paulsen, A ^a,c   D'Agay Abensour, L ^a,b   Hoglund P ^a   Rambaud, J C ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Hopital Saint Lazare   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Aprotinin; Arginine vasopressin; Bioavailability; DDAVP; Enzyme inhibitor; Gastrointestinal tract; Healthy volunteer; Pharmacokinetics

Indexed keywords

APROTININ; CHYMOTRYPSIN; DESMOPRESSIN; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; APROTININ; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHYMOTRYPSIN; DEAMINO ARGININE VASOPRESSIN; DRUG INTERACTIONS; DUODENUM; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SERINE PROTEINASE INHIBITORS; TRYPSIN INHIBITORS;

EID: 0029784753     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050146     Document Type: Article

References (27)

1. Andersson K-E, Arner B (1972) Effects on dDAVP, a synthetic analogue of vasopressin, in patients with central diabetes insipidus. Acta Med Scand 192:21-27
2. d'Agay-Abensour L, Fjellestad-Paulsen A, Höglund P, Ngô Y, Paulsen O, Rambaud JC (1993) Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. Eur J Clin Pharmacol 44:473-476
3. Deurloo MJM, Hermens WAJJ, Romeijn SG, Verhoef J Merkus FWHM (1989) Absorption enhancement of intranasally administered insulin by sodium taurodihydrofusidate in rabbits and rats. Pharm Res 6:853-856
4. Dlugosz J, Fölsch UR, Creutzfeldt W (1983) Inhibition of intraduodenal trypsin does not stimulate exocrine pancreatic secretion in man. Digestion 26:197-204
5. Figarella C, Taulier J, Sarles H (1965) Determination of chymotrypsin and trypsin in duodenal content. Bull Soc Chim Biol 47:679-686
6. Fjellestad A, Czernichow P (1986) Central diabetes insipidus in children. Oral treatment with a vasopressin hormone analog (DDAVP). Acta Paediatr Scand 75:605-610
7. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris AS, Czernichow P (1987) Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine-vasopressin. Acta Endocrinol (Copenh) 115:307-312
8. Fjellestad-Paulsen A, Laborde K, Kindermans C, Czernichow P (1993a) Water balance hormones during long-term follow-up of oral dDAVP treatment in diabetes insipidus. Acta Paediatr Scand 82:752-757
9. Fjellestad-Paulsen A, Höglund P, Lundin S, Paulsen O (1993b) Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol 38:177-182
10. Fjellestad-Paulsen A, Söderberg-Ahlm C, Lundin S (1995) Metabolism of vasopressin. oxytocin and their analogues in the human gastrointestinal tract. Peptides 16:1141-1147
11. Frey EK, Kraut H, Werle E (eds) (1967) Das Kallikrein-kinin-system und seine Inhibitoren, Enke-Verlag, Stuttgart, p 126
12. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
13. Hammer M, Vilhardt H (1985) Peroral treatment of diabetes insipidus with a polypeptide hormone analog, desmopressin. J Pharmacol Exp Ther 234:754-760
14. Hyden S (1955) A turbimetric method for the determination of high polyethylene glycols in biological materials. Ann R Agric 22: 139-145
15. Loo JC, Riegelman S (1968) New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 6: 918-928
16. Lundin S, Vilhardt H (1986) Absorption of 1-deamino-8-D-arginine vasopressin from different regions of the gastro-intestinal tract in rabbits. Acta Endocrinol (Copenh) 112:457-460
17. Lundin S, Melin P, Vilhardt H (1985) Plasma concentrations of 1-deamino-8-D-arginine vasopressin after intragastric administration in the rat. Acta Endocrinol (Copenh) 108: 170-183
18. Lundin S, Pantzar N, Broeders A, Ohlin M, Weström BR (1991) Differences in transport rate of oxytocin and vasopressin analogues across proximal and distal isolated segments of the small intestine of the rat. Pharm Res 8: 1274-280
19. Marcuis-Mouren G, Sarda L, Desnuelle P (1959) Purification of dog pancreatic lipase. Arch Biochem Biophys 82:309-319
20. Markwardt F (1978) Naturally occurring inhibitors of fibinolysis In: Markwardt F (ed) Fibrinolytics and antitibrinolytics. Springer, Berlin. Heidelberg New York, pp 487-509
21. Modigliani R, Rambaud J-C, Bernier JJ (1973) The method of intraluminal perfusion of the human small intestine. Principle and technique. Digestion 9: 176-192
22. Morimoto K, Yanaguchi H, Iwakura Y, Miyazaki M, Nakatani E, Iwamoto T, Ohashi Y, Nakai Y (1991) Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Pharm Res 8:1175-1179
23. Morishita I, Morishita M, Takayama K, Machida Y, Nagai T (1992) Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int J Pharmaceut 78:9-16
24. Owens DR, Vora JP, Birtwell J, Luzio S, Hayes TM (1988) The influence of aprotinin on regional absorption of soluble human insulin. Br J Clin Pharmacol 25: 453-456
25. Saffran M, Bedra C, Kumar GS, Neckers DC (1988) Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J Pharmaceutical Sci 77:33-38
26. Statistical Consultants Inc. (1986) PCNONLIN and NONL1N84: Software for the statistical analysis of nonlinear models. Am Statist 40:52
27. Vilhardt H, Lundin S, Falch J (1986) Plasma kinetics of dDAVP in man. Acta Pharmacol Toxicol 58:379-381